Axelar attends BIO-Europe partnering conference in Berlin, Germany

Axelar AB will attend the 23rd annual BIO-Europe conference in Berlin, Germany on November 6-8, 2017 to meet with potential partners and investors. The BIO-Europe conference is Europe's largest partnering conference serving the global biotechnology industry. Delegates from all parts of the biotechnology value chain come to BIO-Europe to quickly identify, engage and enter into strategic relationships that drive their businesses successfully forward.

About AXL1717 (picropodophyllin)

AXL1717 is an orally bioavailable small molecule with dual mechanisms of action, which has been shown to pass through the blood-brain barrier. AXL1717 targets the IGF-1R signaling pathway but does not bind the IGF-1R. AXL1717 has also been shown to yield cell cycle arrest in mitosis, due to indirect effects on microtubule dynamics, making it a unique anti-cancer drug.

About Axelar AB

Axelar is a Swedish drug development company developing targeted oral anti-cancer therapies for indications where there are significant unmet medical needs. The company was founded based on research performed at Karolinska Institutet, Stockholm and the discovery of a group of compounds that target the IGF-1 receptor signaling pathway without affecting signaling from the closely related insulin receptor.

For additional information about Axelar, please visit www.axelar.se.